New study does anyone understand this, Ot

OncologyStat^®One Source, Many Resources.^® By Elsevier Journal Scans Identification of Subtypes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome Genetic Profiling Reveals Prognostic Signatures for HER2 Subtypes J Staaf, M Ringnér, J Vallon-Christersson, G Jönsson, PO Bendahl, K Holm, A Arason, H Gunnarsson, C Hegardt, BA Agnarsson, L Luts, D Grabau, M Fernö, PO Malmström, OT Johannsson, N Loman, RB Barkardottir, A Borg 20100215 2010 Mar 15 J Clin Oncol Journal Content

Find more items about these cancer types:

Breast

Identification of Subtypes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome J Clin Oncol. 2010 Mar 15; Epub ahead of print, J Staaf, M Ringnér, J Vallon-Christersson, G Jönsson, PO Bendahl, K Holm, A Arason, H Gunnarsson, C Hegardt, BA Agnarsson, L Luts, D Grabau, M Fernö, PO Malmström, OT Johannsson, N Loman, RB Barkardottir, A BorgInvestigators identified 3 distinct HER2 molecular subtypes, one of which was independently prognostic for poor outcomes.Supplementary editorial provided by OncologySTATTAKE-HOME MESSAGEInvestigators identified 3 distinct HER2 molecular subtypes, one of which was independently prognostic for poor outcomes.STUDY IN CONTEXTHER2-positive breast cancers generally confer a poor prognosis, having variable response to chemotherapy. Certain HER2-positive tumors start out, or later become, resistant to targeted therapy with trastuzumab. Thus, improved stratification of HER2-positive tumor subtypes is needed. In this study by Staaf et al, gene expression analysis was used to identify 3 subtypes of HER2-positive disease that were associated with distinct clinical outcomes. One subtype, found to be associated with significantly worse clinical outcome, was used to construct a predictive gene signature (HER2-derived prognostic predictor [HDPP]). Validation studies showed that HDPP was strongly and independently prognostic for poor outcomes, regardless of other factors such as basal-like histology, estrogen-receptor (ER)-negative status, positive lymph node status, and high-grade disease.Hierarchical clustering analysis of expression data from 10,377 genes (Lund HER2 set) was used to identify the 3 HER2 subgroups (clusters). Tumors associated with cluster 2 had worse clinical outcomes than did those associated with clusters 1 and 3. Cluster 2 tumors tended to be ER negative and to overexpress steroid response genes (steroid response-positive phenotype). Tumors in cluster 3 were associated with better overall survival (OS) and distant metastasis-free survival (DMFS) than were those associated with the other 2 clusters. Cluster 3 tumors tended to be smaller in size and associated with fewer involved lymph nodes, but they were also highly proliferative, high-grade tumors with active PI3K signaling. Cluster 1 tumors had similar outcomes to those in cluster 3, but they were less proliferative, of lower grade, had less active PI3K signaling, and displayed an extracellular matrix-positive phenotype.Based on the gene expression clustering, a 158-gene prognostic predictor (HDPP) was constructed. Tumors could now be separated into 2 groups with distinct prognoses, one with poor and one with good OS and DMFS outcomes (log-rank P < .00006 and P < .00009, respectively). In multivariate analyses, HDPP was independently prognostic for both the entire 10-year (P = .02) and the 5-year (P = .05) follow-up periods.Validation studies of HDPP were carried out using several prognostic breast cancer expression datasets. Using the Nederlands Kanker Instituut (NKI) and Erasmus Medical Center (EMC) datasets, HDPP identified a subgroup of patients with good OS and/or DMFS outcomes, independent of ER status. In the NKI dataset, HDPP demonstrated superior capability for prognostic stratification of HER2 tumors when compared with the 70-gene signature (MammaPrint) and the 21-gene recurrence scores (Oncotype DX).In a separate experiment using Affymetrix data (n = 1881), HDPP was also independently prognostic and identified a subgroup of 203 ER-negative, HER2-positive tumors with good DMFS. HDPP was prognostic, regardless of ER and node status, histologic grade, tumor size, and patient age, for both the entire (P = .0002) and the 5-year (P = .0004) follow-up periods.Analysis evaluating the power of HDPP to predict response to treatment showed a significant association for patients of any HER2 status receiving adjuvant tamoxifen. In HER2-positive patients who received neoadjuvant chemotherapy, the majority of patients with residual disease were classified as HDPP poor, while those achieving a pathologic complete response were classified as HDPP good.In this study, Staaf et al constructed a HER2-derived gene signature that was independently prognostic for tumors, conferring a good vs a poor prognosis in HER2-positve breast cancer. HDPP signature may represent a tool for improved outcome prediction in HER2-positive breast cancer.ABSTRACTAccess this article »Community CommentsTotal comments to date: 0 View CommentsPost A Comment(maximum 2000 characters: 2000 remaining)0Enter comments... Thank you for your comments. Your comment has been accepted. Your user id will be tracked with the alert for the moderator regarding this comment. Are you sure you wish to report this comment as offensive? Thank you for your submission. The comment has been flagged and the moderator notified. Comment Print page Share page RSS feeds Editors' ChoiceCEP17 Duplication Predicts Adjuvant Anthracycline Response in Breast Cancer Read more › Welcome to Mobile!Visit from any web-enabled mobile phone or handheld device. Click here Sign up for our newslettersToo busy to follow cancer's top stories? Sign-up for 1 or more of our free newsletters -- delivered weekly to your inbox. Sign-up now  › Category News and Viewpoints News Viewpoints Cancer Policy Forum What Patients Are Reading Videos Journals Journal Scans Review Articles Drugs and Regimens Oncology Drugs Chemotherapy Regimens Conferences Conference Coverage Conference Calendar CME Disease Management Resources Practice Management Career Center Cancer Centers Patient Handouts Related Websites Focus on Europe view all cancer types / view categories Cancer Types Spotlightmore types close Bladder Bone Breast Breast (ER Positive) CNS/Brain Colon and Rectum Endocrine System Esophagus GYN (Non-Ovary) GYN (Ovary) Head and Neck HIV-Related Cancers Bladder Bone Breast Breast (ER Positive) CNS/Brain Colon and Rectum Endocrine System Esophagus GYN (Non-Ovary) GYN (Ovary) Head and Neck HIV-Related Cancers Hodgkin's Lymphoma Kidney (Renal Cell) Leukemia Liver and Bile Duct Lung Multiple Myeloma Myelodysplastic Syndrome Myeloproliferative Diseases Non-Hodgkin's Lymphoma Pancreas Pediatric Cancers Prostate Rare Cancers Skin (Melanoma) Skin (Non-Melanoma) Soft-Tissue Sarcoma Stomach Testicle Breast/ General none none none y Canada Other Health ProfessionalTuesday, April 6, 2010
Advanced Search My Account Logout Elsevier Home Site Map Cancer Types About OncologySTAT Privacy Policy Terms of Use Contact Us Advertise Copyright © 2010 Elsevier Inc. All rights reserved.